The demand for treating neuroinflammatory diseases such as Alzheimer's and MS continues to grow. One company aims to bring to market a unique drug candidate that could significantly help millions of people suffering from such diseases. The cogs are in motion and the company is working diligently to be successful with its lead candidate Foralumab. Lead candidate, intranasal Foralumab, is the World's ONLY fully human anti-CD3 mAb! How significant is anti-CD3 mAb? Well, last year , Sanofi acquired Provention Bio for a staggering $2.9 billion for the company's humanized anti-CD3 monoclonal antibody drug, teplizumab. This company's lead candidate Foralumab has demonstrated a favorable safety profile and clinical response in patients in studies to date. Not long ago the company had exciting news, announcing that it has submitted an FDA request to obtain an Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation!
|
Tuesday, June 4, 2024
NASDAQ biotech company is working on a Wonder Drug' that could fight Alzheimer's, ALS, and other diseases.
Subscribe to:
Post Comments (Atom)
What a year of no haircuts taught me about growing strong, healthy hair
The 8 Shoe Trends You'll See Everywhere In 2025 VIEW IN BROWSER ...
-
insidecroydon posted: " Become a Patron! What's on inside Croydon: Click here for the latest events listing...
No comments:
Post a Comment